
Medically Reviewed By
Dr. Neha Gupta ( Medical Oncology)
A definitive oncological review on Metastatic Castration-Resistant Prostate Cancer (mCRPC), detailing PSA kinetics, second-generation androgen receptor axis-targeted therapies (Enzalutamide, Abiraterone), homologous recombination repair (HRR/BRCA) testing for PARP inhibitors, and Theranostic 177Lu-PSMA-617 therapy.
CRITICAL CLINICAL RED FLAG: Patients with prostate cancer on androgen deprivation therapy (ADT) who exhibit consecutive rising PSA levels (>2 ng/mL above nadir) or new persistent bone pain require urgent 68Ga-PSMA-11 PET-CT imaging to detect early castration-resistant metastasis.
Despite initial suppression of serum testosterone (<50 ng/dL) with LHRH agonists, prostate cancer cells adapt through AR gene amplification, point mutations, and intracrine steroid synthesis, progressing to Castration-Resistant Prostate Cancer (CRPC).
PSA Velocity & Doubling Time: A doubling time of <6 months identifies high risk of rapid skeletal metastasis.
68Ga-PSMA PET-CT: Unsurpassed sensitivity in detecting millimeter-sized pelvic nodal and bone marrow metastases.
Germline & Somatic HRR Gene Testing: Identifies BRCA1, BRCA2, ATM, and CDK12 mutations in up to 25% of mCRPC patients.
Combining modern AR pathway inhibitors with continuous ADT extends overall survival by years:
Enzalutamide / Apalutamide / Darolutamide: Potent androgen receptor antagonists that prevent AR nuclear translocation and DNA binding.
Abiraterone Acetate + Prednisone: Selective CYP17 enzyme inhibitor blocking androgen biosynthesis in the testes, adrenals, and tumor tissue.
PARP Inhibitors (Olaparib / Rucaparib): Induce synthetic lethality in HRR-mutated mCRPC, extending radiographic progression-free survival (PROfound trial).
"Theranostics embodies the pinnacle of precision oncology: if we can see the tumor on a diagnostic PSMA scan, we can deliver targeted beta-radiation directly to destroy the cancer cells from within." — Dr. Neha Gupta

177Lu-PSMA-617 binds selectively to Prostate-Specific Membrane Antigen (PSMA) overexpressed on prostate carcinoma cells, delivering localized cytotoxic beta-radiation over a 1 to 2 mm radius while sparing healthy tissues.
CLINICAL CAUTION: PSMA-PET imaging must show high tumor PSMA avidity (SUVmax > 1.5x liver uptake) and absence of PSMA-negative discordant FDG-avid lesions to qualify for 177Lu-PSMA-617 radioligand therapy.
Mandatory co-administration of bone-targeting antiresorptive agents (Denosumab 120 mg subcutaneous q4w or Zoledronic Acid) with oral calcium and vitamin D prevents pathological fractures, cord compression, and severe bone pain.
1. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer (VISION Trial) — NEJM, 2021; 385: 1091-1103.
2. Olaparib for Metastatic Castration-Resistant Prostate Cancer (PROfound Trial) — NEJM, 2020; 382: 2091-2102.

Senior Consultant & Clinical Director — Medical Oncology
MBBS (BFUHS Faridkot), MD Radiation Oncology (BFUHS Faridkot), DrNB Medical Oncology (Sarvodaya Hospital, Faridabad), Precision Oncology (Harvard, USA), Ex Consultant RGCI New Delhi

13+ Years Experience
Spica — Grover Hospital
Request a priority OPD appointment or second opinion on your scans.
Proprietary surgical methodologies and precision protocols pioneered by our senior directors to minimize trauma, protect natural anatomy, and accelerate recovery.

Dr. Deepak Garg (Orthopaedic Surgical Oncology - RGCI Delhi Trained) and Dr. Neha Gupta (Medical Oncology) co-lead the Bone Cancer & Sarcoma Center at Spica Healthcare. Integrating intensive multi-agent neoadjuvant chemotherapy protocols (MAP: High-Dose Methotrexate, Doxorubicin, Cisplatin for Osteosarcoma; VIDE: Vincristine, Ifosfamide, Doxorubicin, Etoposide for Ewing Sarcoma) with 3D computer-navigated limb salvage surgery and modular titanium megaprosthetic joint reconstruction, 5-year survival rates exceed 75% to 80% while saving over 95% of patients from limb amputation.
Spica Healthcare — Bone and Cancer Institute, Bathinda — is South-Western Punjab's premier super-speciality centre led by AIIMS and Tata Memorial fellowship-trained directors.
Every diagnostic MRI review, surgical staging, and operation is personally directed by chief clinical specialists — Dr. Deepak Garg (Orthopaedic Oncology & Robotics) and Dr. Neha Gupta (Medical Oncology) — guaranteeing zero junior proxies.
Sub-millimeter implant positioning and soft-tissue ligament balancing ensuring patients walk comfortably within 24 hours of total knee replacement.
South-West Punjab's only dedicated centre for modular titanium megaprosthesis, saving natural limbs and functions in 95%+ of bone cancer patients.
Full cashless coverage for Ayushman Bharat (PM-JAY), Punjab Govt Health Schemes, ECHS, and 30+ private insurance networks with on-desk approvals.
Positive-pressure HEPA filtered theatres minimizing infection rates below international benchmarks with 24/7 dedicated critical care backup.
Fellowship-trained surgical directors from AIIMS & Tata Memorial providing compassionate, world-class tertiary care in super-speciality orthopaedics and medical oncology.

Senior Consultant & Clinical Director — Medical Oncology
MBBS (BFUHS Faridkot), MD Radiation Oncology (BFUHS Faridkot), DrNB Medical Oncology (Sarvodaya Hospital, Faridabad), Precision Oncology (Harvard, USA), Ex Consultant RGCI New Delhi


Senior Consultant & Clinical Director — Orthopaedic Oncology & Robotic Joint Surgery
16+ Yrs ExpSenior Consultant & Clinical Director — Orthopaedic Oncology & Robotic Joint Surgery
MBBS (TNMC Mumbai), DNB Orthopaedics (PGI & SP Miraj), Fellowship Arthroplasty and Arthroscopy (Fortis Hospital, New Delhi), Fellowship Orthopaedic Oncology (Rajiv Gandhi Cancer Institute, New Delhi)
Free OPD screening camps, director-led masterclasses, and national oncology representations by Spica Healthcare.
Real stories from patients who recovered through limb preservation surgery, 3D robotic joint replacements, and precision cancer care at Spica Healthcare — Grover Hospital, Bathinda.
Evidence-based surgical recovery roadmaps, robotic joint protocols, and precision oncology insights written by our clinical directors.